NT-219 is under clinical development by Purple Biotech and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And ...

PMN in the mastitic milk were counted using Gram staining. Further, somatic cell counts (SCC), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, IL-10 and serum amyloid A (SAA) concentrations ...

The company’s IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both NK cells and T cells to demonstrate a robust, localized immune response within the tumor ...